SBI Holdings, Inc., together with its subsidiaries, engages in the online financial service businesses and investment activities in Japan and internationally. It operates through Financial Services Business, Asset Management Business, and Biotechnology-Related Business segments. The Financial Services Business segment provides various financial products and services, including brokerage and investment banking, banking, nonlife insurance and short-term small-amount insurance, and housing loan services; and credit card, leasing, remittance, peer-to-peer lending, and other services, as well as foreign-exchange market participant services. This segment operates proprietary trading system, which allows investors to trade stocks and bonds through electronic trading systems without stock exchanges. The Asset Management Business segment is involved in the venture capital, buyout investment, and financial and economic information activities. This segment also provides asset management services; and invests in hedge funds and private equity funds. The Biotechnology-Related Business segment develops, distributes, and sells pharmaceutical products, health foods, and cosmetics with 5-ALA as ingredient. This segment is also involved in the research and development of treatment methods and pharmaceuticals in autoimmune diseases and cancer fields. The company is also involved in the operation of various online intermediate services; development and trading of investment properties; provision of guarantee services for house rentals; and manufacture of mining chips, and development of mining systems. The company was formerly known as Softbank Investment Corporation and changed its name to SBI Holdings, Inc. in July 2005. SBI Holdings, Inc. was founded in 1999 and is headquartered in Tokyo, Japan.
Read More
